리튬 또는 발프로산으로 치료받은 양극성장애 환자의 무증상 갑상선저하증
Subclinical Hypothyroidism in Patients with Bipolar Disorders Managed by Lithium or Valproic Acid
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: To investigate the pattern of subclinical hypothyroidism (SCH) in patients with bipolar disorders managed by lithium or valproic acid. Methods: The study participants were 106 patients with DSM-IV bipolar disorders receiving planned maintenance treatment at the Mood Disorders Clinic of Seoul National University Bundang Hospital (aged between 17 and 64, mean duration of follow-up = 875.65 days). Using the bipolar disorder registry, thyroid function data were analyzed to assess the frequency of and the risk factors for SCH in patients managed by lithium (n = 64) or valproic acid (n = 42) for more than 5 months. Results: Overall frequencies of SCH were 20.3% (13/64) in the lithium group, 14.3% (6/42) in the valproic acid group, and between the two groups there is no difference (p = 0.43). No differences were observed in the potential risk factors for SCH between the two groups including age, sex, subtype of bipolar disorder, baseline TSH, and concomitant antipsychotic use. In cases with SCH, thyroid-stimulating hormone (TSH) showed a tendency to increase at 3 month after the initiation of lithium or valproic acid. A gradual increase in the number of patients showing SCH was found within the first 3 years of medication. Conclusions: With regular monitoring and careful assessment, there was no difference in the risk of SCH between lithium and valproic acid maintenance. The risk of mood stabilizer-associated SCH may gradually increase within 3 years following the commencement of medication, thereby mandating close monitoring for the first 3 years of treatment. Further studies with large sample size would be needed to confirm these findings.
Abstract
Objectives: To investigate the pattern of subclinical hypothyroidism (SCH) in patients with bipolar disorders managed by lithium or valproic acid. Methods: The study participants were 106 patients with DSM-IV bipolar disorders receiving planned maintenance treatment at the Mood Disorders Clinic of Seoul National University Bundang Hospital (aged between 17 and 64, mean duration of follow-up = 875.65 days). Using the bipolar disorder registry, thyroid function data were analyzed to assess the frequency of and the risk factors for SCH in patients managed by lithium (n = 64) or valproic acid (n = 42) for more than 5 months. Results: Overall frequencies of SCH were 20.3% (13/64) in the lithium group, 14.3% (6/42) in the valproic acid group, and between the two groups there is no difference (p = 0.43). No differences were observed in the potential risk factors for SCH between the two groups including age, sex, subtype of bipolar disorder, baseline TSH, and concomitant antipsychotic use. In cases with SCH, thyroid-stimulating hormone (TSH) showed a tendency to increase at 3 month after the initiation of lithium or valproic acid. A gradual increase in the number of patients showing SCH was found within the first 3 years of medication. Conclusions: With regular monitoring and careful assessment, there was no difference in the risk of SCH between lithium and valproic acid maintenance. The risk of mood stabilizer-associated SCH may gradually increase within 3 years following the commencement of medication, thereby mandating close monitoring for the first 3 years of treatment. Further studies with large sample size would be needed to confirm these findings.
참고문헌 (31)
- Bauer M, "The thyroid-brain interaction in thyroid disorders and mood disorders", J Neuroendocrinol, 20, pp.1101~1114 (2008)
- Bunevicius R, "Psychiatric manifestations of Graves’ hyperthyroidism: pathophysiology and treatment options", CNS Drugs, 20, pp.897~909 (2006)
- Howland RH, "Thyroid dysfunction in refractory depression: implications for pathophysiology and treatment", J Clin Psychiatry, 54, pp.47~54 (1993)
- Müller-Oerlinghausen B, "Bipolar disorder", Lancet, 359, pp.241~247 (2002)
- Kupka RW, "Rapid and non-rapid cycling bipolar disorder: a meta-analysis of clinical studies", J Clin Psychiatry, 64, pp.1483~1494 (2003)
- Vonk R, "Is autoimmune thyroiditis part of the genetic vulnerability (or an endophenotype) for bipolar disorder?", Biol Psychiatry, 62, pp.135~140 (2007)
- Bou Khalil R, "Thyroid adverse effects of psychotropic drugs: a review", Clin Neuropharmacol, 34, pp.248~255 (2011)
- Bocchetta A, "Loviselli A. Ten-year follow-up of thyroid function in lithium patients", J Clin Psychopharmacol, 21, pp.594~598 (2001)
- Vainionpää LK, "Thyroid function in girls with epilepsy with carbamazepine, oxcarbazepine, or valproate monotherapy and after withdrawal of medication", Epilepsia, 45, pp.197~203 (2004)
- Park YM, "Decreased thyroid function in Korean women with bipolar disorder receiving valproic acid", Gen Hosp Psychiatry, 33(200), pp.200.e13~200.e15 (2011)
- Kelly DL, "Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine", J Clin Psychiatry, 66, pp.80~84 (2005)
- Rodondi N, "Subclinical hypothyroidism and cardiovascular risk: how to end the controversy", J Clin Endocrinol Metab, 98, pp.2267~2269 (2013)
- Rodondi N, "Subclinical hypothyroidism and the risk of coronary heart disease and mortality", JAMA, 304, pp.1365~1374 (2010)
- Zhu DF, "fMRI revealed neural substrate for reversible working memory dysfunction in subclinical hypothyroidism", Brain, 129(Pt 11), pp.2923~2930 (2006)
- Baldini M, "Neuropsychological functions and metabolic aspects in subclinical hypothyroidism: the effects of L-thyroxine", Prog Neuropsychopharmacol Biol Psychiatry, 33, pp.854~859 (2009)
- Demartini B, "Prevalence of depression in patients affected by subclinical hypothyroidism", Panminerva Med, 52, pp.277~282 (2010)
- Waldman SA, "Myxedema coma associated with lithium therapy", Am J Med, 87, pp.355~356 (1989)
- Bocchetta A, "Fifteen-year follow-up of thyroid function in lithium patients", J Endocrinol Invest, 30, pp.363~366 (2007)
- Bocchetta A, "The course of thyroid abnormalities during lithium treatment: a two-year follow-up study", Acta Psychiatr Scand, 86, pp.38~41 (1992)
- Mikati MA, "Risk factors for development of subclinical hypothyroidism during valproic acid therapy", J Pediatr, 151, pp.178~181 (2007)
- Gardner DM, "International consensus study of antipsychotic dosing", Am J Psychiatry, 167, pp.686~693 (2010)
- Helfand M, "U.S. Preventive Services Task Force. Screening for subclinical thyroid dysfunction in nonpregnant adults: a summary of the evidence for the U.S. Preventive Services Task Force", Ann Intern Med, 140, pp.128~141 (2004)
- Lazarus JH, "Lithium and thyroid", Best Pract Res Clin Endocrinol Metab, 23, pp.723~733 (2009)
- Bocchetta A, "Thyroid abnormalities during lithium treatment", Acta Psychiatr Scand, 83, pp.193~198 (1991)
- Vincent A, "Early onset of lithium-associated hypothyroidism", J Psychiatry Neurosci, 18, pp.74~77 (1993)
- Qiu L, "Effect of antipsychotics on serum level of thyroid hormones in schizophrenic patients", Laboratory Medicine, 1, pp.18~ (2007)
- Maarbjerg K, "Changes in serum thyroxine (T4) and serum thyroid stimulating hormone (TSH) during prolonged lithium treatment", Acta Psychiatr Scand, 75, pp.217~221 (1987)
- Emerson CH, "Serum thyrotropin and thyroxine concentrations in patients recieving lithium carbonate", J Clin Endocrinol Metab, 36, pp.338~346 (1973)
- Zimmermann MB, "The impact of iron and selenium deficiencies on iodine and thyroid metabolism: biochemistry and relevance to public health", Thyroid, 12, pp.867~878 (2002)
- Graf WD, "Altered antioxidant enzyme activities in children with a serious adverse experience related to valproic acid therapy", Neuropediatrics, 29, pp.195~201 (1998)
- Fagiolini A, "Hypothyroidism in patients with bipolar I disorder treated primarily with lithium", Epidemiol Psichiatr Soc, 15, pp.123~127 (2006)